Loading...
•
Jun 30, 2023
Integra LifeSciences Q2 2023 Earnings Report
Integra LifeSciences' financial performance declined in Q2 2023 due to the Boston recall, but the underlying business showed resilience with solid mid-single digit organic growth.
Key Takeaways
Integra LifeSciences reported a decrease in revenue and earnings per share for Q2 2023 compared to the previous year. Total revenues were $381.3 million, a 4.2% decrease, and GAAP earnings per diluted share were $0.05, compared to $0.54 in the prior year. The company is updating its full-year 2023 revenue and adjusted EPS guidance to $1.548 billion to $1.560 billion and $3.10 to $3.18, respectively.
Second quarter revenues of $381.3 million declined 4.2% on a reported basis and declined 2.7% on an organic basis compared to the prior year.
Second quarter GAAP earnings per diluted share of $0.05, compared to $0.54 in the prior year; adjusted earnings per diluted share of $0.71, compared to $0.82 in the prior year.
The strong organic growth of our Codman Specialty Surgical segment and several product lines in our Tissue Technologies business demonstrate the resilience of our diversified portfolio of leading brands and technologies and strong market recovery.
Planning a $125 million share repurchase in the third quarter.
Forward Guidance
For the full year 2023, the Company is updating its revenue and adjusted EPS expectations to $1.548 to $1.560 billion and $3.10 to $3.18, respectively. For the third quarter 2023, the Company expects reported revenues in the range of $386 million to $390 million, and adjusted earnings per diluted share are expected to be in the range of $0.76 to $0.80.
Positive Outlook
- Revenue range represents reported growth of -0.6% to 0.2%, with organic growth of 0.3% to 1.1%.
- Guidance reflects the full year impact of the Boston recall and the solid performance of the underlying business.
- Third quarter revenue represents reported growth of 0.2% to 1.3% and organic growth of 0.3% to 1.3%.
- Company expects to restart manufacturing at the Boston facility late Q4’23 and resume commercial distribution in mid- to late Q2’24.
- Relaunch of CereLink® expected late Q3’23 in international markets and late Q4’23 in the US.
Challenges Ahead
- Full year revenue growth impacted by Boston recall.
- Q2 revenues declined 4.2% on a reported basis and declined 2.7% on an organic basis compared to the prior year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...